Prostate Cancer Blog

Towards An Understanding Of The Possible Future Role Of Combining Chemotherapy With Immunotherapy – On The Horizon

There was a study published in the journal Nature that described a promising new combination therapy for the treatment of men with advanced prostate cancers that are non-responsive to chemotherapy. The study is entitled "Immunosuppressive Plasma Cells Impede T-Cell Dependent Immunogenic Chemotherapy." The study was conducted at the University of California, San Diego. Prostate cancers [...]

By Malecare|2017-10-19T10:47:20-04:00May 29th, 2015|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials & Research, Combination Therapy, Immunosuppressive B cells, oxaliplatin, Research, Uncategorized|0 Comments

Evaluating The Side Effects Of Docetaxel (Taxotere) vs Cabazitaxel (Jevtana)

Many men express great hesitation to move to chemotherapy with both docetaxel (taxotere) and cabazitaxel (Jevtana) because of the side effects which can include alopecia (hair loss), nail changes, neuropathy, and dysgeusia (a distortion of the sense of taste). A group of researchers hypothesized that the adverse side effects (AE) of these two chemotherapy drugs, [...]

By Malecare|2020-02-04T11:37:16-05:00May 26th, 2015|Advanced Prostate Cancer, Cabazitaxel, Chemotherapy, docetaxel, Jevtana, peripheral neuropathy, Side Effects, taxotere, Uncategorized|1 Comment

The PREVAIL Trial Shows That Enzalutamide Not Only Increases Overall Survival Over Placebo, It Also Delays the Onset Of The First Skeletal Event

Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC). Now, an additional analysis of the data has shown the effect enzalutamide also has on [...]

By Malecare|2020-02-04T11:37:24-05:00May 22nd, 2015|Advanced Prostate Cancer, Bones and Prostate Cancer, Clinical Trials, enzalutamide, Quality of Life, survival, Uncategorized, Xtandi|0 Comments

SEER PSA Data Is Flawed and Removed By the NCI – What Are the Implications for the Flawed USPTF PSA Debacle?

I am not sure what to do with this information, but it certainly could be described as a rather large elephant in the room. We all are very familiar with the prostate cancer PSA test controversy brought on by the United States Preventive Task Force (USPTF). To quickly review the issue, the USPTF developed a [...]

By Malecare|2017-10-19T10:47:21-04:00May 20th, 2015|Advanced Prostate Cancer, General Information, PSA, Research, Screening, Uncategorized, USPTF|0 Comments

The Development of A Novel Blood Biomarker for Detecting AR-V7 and Resistance to Zytiga and Xtandi

At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer. Their work relies on the premise that AR-V7 expression underlies resistance [...]

By Malecare|2021-02-22T10:05:38-05:00May 19th, 2015|abiraterone acetate, Advanced Prostate Cancer, AUA, biomarkers, CTCs, enzalutamide, Research, Uncategorized, Xtandi, Zytiga|1 Comment

Predicting the Long-Term Survival of Men with A Biochemical Recurrence Post-Surgery Who Are Hormone Naive Can Change How We Treat Them

Appearing in the European Journal of Nuclear Medicine and Molecular Imaging a recent study provides data on the long-term survival of men with a biochemical recurrence after failed surgery. In the study by Giovacchini et al. it was shown that a PET/CT scan (specifically a [11C] choline PET/CT) could predict the long-term survival of men [...]

By Malecare|2021-02-17T10:30:29-05:00May 14th, 2015|[11C] choline PET/CT, Advanced Prostate Cancer, Bio Chemical Recurrence, CT Scans, General Information, Research, survival, survivorship, Uncategorized|0 Comments

Is Delaying The Start of ADT Safe for Prostate Cancer Patients?

A recently previewed (prior to the upcoming ASCO Annual Meeting) of a large study shows that men with prostate cancer who had a PSA-based relapse (Biochemical Recurrence) could delay starting androgen deprivation therapy (ADT) until they started experiencing symptoms from the cancer. They found that this delay would not affect the men’s long-term survival. The [...]

By Malecare|2021-02-17T10:30:41-05:00May 12th, 2015|ADT, Advanced Prostate Cancer, Bio Chemical Recurrence, Clinical Trials & Research, Disease Progression, Drugs & Treatments, Uncategorized|0 Comments

Cardiovascular Disease And Its Relationship With Androgen Deprivation (ADT)

Clinicians believe that there is an association between the risk of cardiovascular disease (CVD) and the duration and type of androgen-deprivation therapy (ADT) in men with prostate cancer. Researchers took data from 2006 to 2012 on filled drug prescriptions from the Swedish national health care registers. A cohort of 41,362 men with prostate cancer who were on ADT [...]

By Malecare|2020-02-04T11:37:12-05:00May 8th, 2015|ADT, Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, Uncategorized|0 Comments

Is Advanced Prostate Cancer Changing? The Evolution of Metastatic Castrate Resistant Prostate Cancer And The Need To Make Some Research Changes

Metastatic castration-resistant prostate cancer (mCRPC) is known as a cancer that more often than not metastasizes to the bone. Less often it moves to nonosseous sites (soft tissue sites like lymph nodes, liver and lung). The last few years has seen the development of new drugs that extend the survival of men. Because of these [...]

By Malecare|2020-02-04T11:37:20-05:00May 6th, 2015|Advanced Prostate Cancer, Bone Metastases, Bones and Prostate Cancer, Clinical Trials, nonosseous metastasis, Uncategorized, Understanding Advanced Prostate Cancer|0 Comments

Predicting Who Will Have A Positive Result From Abiraterone (Zytiga) In Men With Metastatic Castrate Resistant Prostate Cancer

We have many new drugs to treat metastatic castrate resistant prostate cancer (mCRPC), but not all men have a positive result to each of the drug. Understanding who might obtain a positive result to a specific drug prior giving it will save both the individual man and society time and money. Understanding this it becomes [...]

By Malecare|2020-02-04T11:36:55-05:00May 5th, 2015|abiraterone acetate, Advanced Prostate Cancer, Biomarkers and Prognostic Tools, Drugs & Treatments, prognostic tools, Uncategorized, Zytiga|2 Comments